CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE Reports Third Quarter 2021 Financial Results

Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business

Read more

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, November 18, 2021 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Read more

CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search…

Read more

CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, October 28, 2021 (GLOBE NEWSWIRE

  • FTD is a rapidly progressing neurodegenerative disease; up to…

Read more

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the World

CAMBRIDGE,…

Read more

CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 29, 2021 (GLOBE NEWSWIRE)

  • Collaborative research utilized insights gained from CENTOGENE’s…

Read more

CENTOGENE Reports Second Quarter 2021 Financial Results

Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank…

Read more

CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 1, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Read more

CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused…

Read more

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused…

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads